A., E., J.F., M., K., S., L., P., P.D., M., I.Y., W., . . . C.E.M., G. (2023). Efficacy of ixekizumab in patients with moderate-to-severe plaque psoriasis and prediabetes or type 2 diabetes.
Chicago Style CitationA., Egeberg, Merola J.F., Schäkel K., Puig L., Mahar P.D., Wang I.Y., Pavo I., Schuster C., and Griffiths C.E.M. Efficacy of Ixekizumab in Patients With Moderate-to-severe Plaque Psoriasis and Prediabetes or Type 2 Diabetes. 2023.
MLA CitationA., Egeberg, et al. Efficacy of Ixekizumab in Patients With Moderate-to-severe Plaque Psoriasis and Prediabetes or Type 2 Diabetes. 2023.
Warning: These citations may not always be 100% accurate.